Proton-pump inhibitor use in combination with a CDK4/6 inhibitor: is formulation the issue?
Calum Polwart · 2026
Read Proton-pump inhibitor use in combination with a CDK4/6 inhibitor: is formulation the issue? by Calum Polwart (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13446214.txt.
Description
Polwart writes a letter to the editor about a study by Chen and colleagues. The study linked acid drugs, called proton-pump inhibitors, with worse results on palbociclib. Palbociclib treats breast cancer. Polwart notes a key point the study left out. In 2020 the drug changed from a capsule to a tablet. Acid drugs cut how much of the capsule form the body took up. Tests did not show that problem with the tablet form.
Polwart also warns that the acid drug group was less well at the start. Poor health, not the acid drug, may explain the worse results. Broad warnings built on the old capsule may mislead new staff, he argues.
Catalog record
| CREATOR | Calum Polwart |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |